Alvotech's AVT80 BLA Accepted by FDA for Subcutaneous Entyvio Biosimilar

Analysts have lifted their fair value estimate for Amneal Pharmaceuticals to about US$22.71 per share from US$22.00, with price targets from UBS, JPMorgan, Oppenheimer, Barclays and Leerink clustering in the US$20 to US$27 range. UBS points to Amneal's Q2 performance, updated outlook and upcoming biosimilar and generic launches as support for its raised targets in the mid US$20s, while Oppenheimer calls the company a fundamental inflection, citing differentiated launches, the Kashiv acquisition and a vertically integrated biosimilars platform targeting US$1b to US$1.3b of revenue by 2030. Leerink and JPMorgan highlight Affordable Medicines, biosimilars and the Crexont and lanreotide franchises as growth contributors, and Barclays flags the pending gLanreotide approval as a potential clearing event behind its raised US$20 price target. In the updated models, the long-term revenue growth assumption eased to about 9.10% from about 9.60%, the projected net profit margin edged up to about 9.98% from about 9.85%, and the assumed future P/E multiple rose to about 23.2x from about 22.4x, while the discount rate held at about 7.24%.

Johnson & Johnson is scheduled to report its third-quarter 2026 results on Oct. 13, with investors focused on sales performance in its Innovative Medicine segment. The segment has posted five consecutive quarters of sales above $15 billion despite the loss of exclusivity of Stelara, and J&J expects continued above-market growth driven by Darzalex, Erleada, Carvykti, Tecvayli and Rybrevant/Lazcluze in oncology, Tremfya and other immunology products, and Spravato and Caplyta in neuroscience. Newer launches are expected to contribute more than in the second quarter, with Inlexzo sales more than doubling sequentially from around $30 million in the first quarter, while investors will watch for initial sales of the newly launched plaque psoriasis pill Icotyde and Imaavy, approved in the United States in August for a second indication, warm autoimmune hemolytic anemia. Stelara's loss of exclusivity cut the segment's growth by 760 basis points in the second quarter, and the negative impact is expected to be steeper in the third quarter, with biosimilar competition from Amgen, Teva Pharmaceutical Industries and Samsung Bioepis/Sandoz, along with declining Imbruvica sales and European biosimilars for Simponi and a U.S. generic version of Opsumit, weighing on results. Overall, Innovative Medicine is expected to have been J&J's principal growth engine in the quarter, with oncology providing the strongest contribution and Tremfya helping offset Stelara's biosimilar-driven decline.